Social Sentiment for AKBA
Bullish vs. Bearish opinions
Weighted Sentiment 0.00
Akebia Therapeutics Forecast and Stock Analysis
Technical AKBA stock analysis for Thursday May 23, 2019.
|Price to book||USD 1.16|
|Next Earnings Date||2019-08-05|
Akebia Therapeutics fell by -5.57% in the last day ( Thursday, 23rd May 2019 ) from $5.57 to $5.26 and has now fallen 3 days in a row. During day the stock fluctuated 7.05% from a day low at $5.18 to a day high of $5.54. The price has fallen in 8 of the last 10 days and is down by -11.15% for this period. Volume has increased in the last day by 0.50 million shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 1.18 million shares bought and sold for approximately $6.20 million.
- 30 day high of the AKBA stock price was $6.78 and low was $5.18.
- 90 day high was $9.30 and low was $5.18.
- 52 week high for the Akebia Therapeutics - $11.60 and low - $5.18.
Akebia Therapeutics lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -26.93% during the next 3 months and, with 90% probability hold a price between $3.36 and $5.13 at the end of this period.
There are few to none technical positive signals at the moment. Akebia Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $5.53 and $6.39. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Tuesday May 21, 2019, which indicates further falls until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.
Relative Strength Index (RSI)
The stock currently holds a RSI14 at 25 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.
Support & Resistance
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.37 between high and low, or 7.05%. For the last week, the stock has had a daily average volatility of 4.49%.
Akebia Therapeutics is oversold on RSI14 (25). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
4.49 %Average volatility
Very Low Low Medium High Very High
Akebia Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Sell Candidate to a Strong Sell Candidate.
|Golden Star Signal|
Get competitive edge
The signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives a very good return. From 8.000 stocks usually only a few will trigger a Golden Star Signal per day!
Get access to Golden Star list now
|AKBA $5.26 ($-0.31 -5.57%)|
AKBA is down $0.31 today, but where's it headed in 2019?
|Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month system that more than doubles the S&P 500.
This report is free today for StockInvest.us readers.
Click here – the AKBA analysis is free »
From Our Blog
- Trading With Moving Average
- Pivot Points
- Accumulated Volume - Support and Resistance
- Volume - The Indicator You Really Need to Know
- We Give Back!
- Better Buy: Amazon vs. Facebook
- Better Buy: Apple vs. Microsoft
- Relative Strength Index (RSI)
- How to Lose Money When Trading: Part 2
- How to Lose Money When Trading: A Trader is Born
- Our 2017 Christmas Donation
- The Golden Star
- Announcing Partnership With CityFALCON
- Why correct moving average matters
- NASDAQ down -4.17%. Our portfolio is up +8.56%
- New Feature Added: Golden Star Signal
- Pick a Winner With StockInvest.us